Halofuginone mediated protection against radiation-induced leg contracture

HISANARI ISHII1, RAJANI CHOUDHURI1, ASKALE MATHIAS1, ANASTASIA L. SOWERS1, KATHLEEN C. FLANDERS2, JOHN A. COOK1 and JAMES B. MITCHELL1

1Radiation Biology Branch and 2Laboratory of Cell Regulation and Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892-1002, USA

Received March 16, 2009; Accepted May 19, 2009

DOI: 10.3892/ijo_00000342

Abstract. Fibrosis of normal tissues often accompanies radiation treatment of cancer. Activation of the transforming growth factor-ß (TGF-ß) signaling pathway is thought to play a major role in radiation-induced fibrosis and has prompted the development and assessment of low molecular weight inhibitors of the pathway. Previous studies with halofuginone have shown it to inhibit TGF-ß signaling in vitro and protect mice from radiation-induced leg contraction (a model for soft tissue fibrosis). The current study confirms these findings for HaCaT cells stimulated with exogenous TGF-ß treatment. Reducing the halofuginone treatment from 7 days/week (used previously) to 5 days/week post-radiation exposure provided significant protection against radiation-induced leg contraction in mice 3 and 4 months post-radiation treatment. Halofuginone treatment was shown to attenuate TGF-ß signaling molecules taken from irradiated skin including TGF-ßRII, pSmad3, Smad7, and TSP1. The latter, TSP1, a co-activator of TGF-ß may serve as a suitable biomarker for monitoring the efficacy of halofuginone should it be evaluated in a clinical setting for protection against radiation-induced fibrosis.

Introduction

Soft tissue fibrosis often occurs in normal tissues following radiation treatment (1-3). Dependent on the severity of the fibrosis, the quality of life for patients treated with radiation can be impaired, thereby necessitating a need for interventions that might protect against and/or mitigate this toxicity. Ionizing radiation can activate the TGF-ß pathway (4,5) and there is considerable evidence that suggests that activation of the TGF-ß pathway is a major contributor to radiation-induced fibrosis (6-8). Radiation activates TGF-ß from its latent form (4,5). Once activated, a series of signal transduction reactions occur starting with binding of TGF-ß to the trans-membrane TGF-ß Type II receptor. This is followed by a recruitment of the TGF-ß Type I receptor and thereafter the formation of Type II/Type I heterodimer which is phosphorylated. This activated complex serves to phosphorylate and activate downstream signaling proteins such as Smad2 and 3, which bind with Smad4 for transport to the nucleus and initiation of transcription that leads to activation and/or repression of gene expression (9). Thus, members of the TGF-ß signaling pathway represent potential molecular targets for inhibition, which upon inhibition might attenuate or even prevent radiation-induced fibrosis. Targeting the TGF-ß signaling pathway has already shown efficacy in pre-clinical models where radiation-induced fibrosis is decreased (10-13).

Halofuginone is a plant derived alkaloid that exhibits anti-fibrotic activity, and inhibition of type I collagen synthesis (14). Halofuginone has been shown to protect against radiation-induced soft tissue fibrosis by virtue of inhibiting various members of the TGF-ß signaling pathway (15). While this study utilized halofuginone in an in vivo model for radiation-induced fibrosis, the mechanistic studies evaluating inhibition of TGF-ß signaling members were conducted using in vitro systems. The present study was designed to extend upon these observations and to specifically determine whether halofuginone treatment would inhibit TGF-ß signaling pathway targets in vivo. The results of the study clearly demonstrate that halofuginone inhibits members of the TGF-ß signaling pathway that are activated by radiation treatment in vivo and thus provides a rationale for clinical evaluation of halofuginone to attenuate radiation-induced soft tissue fibrosis.

Materials and methods

Reagents. Halofuginone (dl-trans-7-bromo-6-chloro-3-[3-(3-hydroxy-2-piperidyl)acetonyl]-4(3H)-quinazolinone hydrobromide) was obtained from Collgard Biopharmaceuticals, Herzliya, Israel. Stock solutions of 1-2 mg/ml were prepared by dissolving crystalline halofuginone in a lactic acid buffer, 0.44 M, pH 4.3, and stored at 4°C where it is stable for at least 4 months. Working solutions for injection of halofuginone (1 or 5 μg/100 μl) were made each day by diluting the stock halofuginone with 0.9% NaCl. The working solution was
used within 1 h of preparation. Mouse monoclonal anti-thrombospondin-I (TSP1) antibody was purchased from Thermo Scientific (Fremont, CA). Rabbit polyclonal anti-Smad2 antibody (Ser465/467) and mouse actin monoclonal antibody was purchased from Millipore Corp. (Temecula, CA). Rabbit anti-phospho Smad2 polyclonal antibody was purchased from Zymed Invitrogen Corp. (Carlsbad, CA). Rabbit monoclonal anti-Smad3 and anti-phosphorylated Smad3 antibody was purchased from Epitomics (Burlingame, CA). Rabbit polyclonal anti-Smad7 antibody (C-term) was purchased from Zymed Laboratories Inc. (South San Francisco, CA). Mouse polyclonal anti-TGF-β type II receptor (TRII) antibody and mouse Smad7 polyclonal antibody was purchased from Novus Biological, Inc. (Littleton, CO). Human TGF-β was purchased from R&D Systems, Inc. (Minneapolis, MN).

Cell studies. Transformed human keratinocyte cell line (HaCaT) was obtained from Dr N.E. Fusenig, (German Cancer Research Center, Heidelberg, Germany) (16). HaCaT cells were maintained in DMEM medium supplemented with 5% fetal calf serum and antibiotics. Cells were grown to ~80% confluence, rinsed with PBS, and switched to medium containing 0.2% serum and incubated overnight. Cells were then treated with halofuginone (250 nM, final concentration) for a total of 24 h; activated TGF-β (2 ng/ml) was added the last 6 h. Following treatment, cells were rinsed with PBS, lysed with RIPA lysis buffer (Santa Cruz Biotechnology) in the presence of sodium orthovanadate and protease inhibitors (Sigma Aldrich). Following 30 min of incubation on ice, the samples were centrifuged at 14,000 x g, and the supernatant protein concentration was determined by DC Protein Assay (Bio-Rad). Protein samples were stored at -70°C for subsequent Western blot analysis. This experiment was replicated twice.

Animal studies. Female C3H/Hen mice, bred in the National Cancer Institute Animal Production Area (Frederick, MD), were used for this study. The mice were 8-10 weeks of age at the time of experimentation and weighed between 20-30 g. All experiments were carried out under the aegis of a protocol approved by the National Cancer Institute Animal Care and Use Committee and were in compliance with the Guide for the Care and Use of Laboratory Animal Resource, National Research Council. Selective irradiation of the right leg was accomplished by placing each un-anesthetized animal into a specially built Lucite jig that immobilized the animal and facilitated ease of extension of the right hind leg into the radiation field. Lead shields designed as a part of the jigs. Some experiments involved local irradiation to the skin of the flank region. In the same way as the leg irradiation, animals (without anesthetics) were placed in customized Lucite jigs that allow for immobilization and selective irradiation of the skin of the flank. Special clamps held the skin without decreasing blood flow to the treatment area as determined previously by laser Doppler studies. A single radiation dose of 35 Gy was delivered to the right flank of the animal. Special care was taken to avoid irradiation of other body parts by using lead shields specifically designed as a part of the jigs. Four animals were in the 5 μg/mouse/day treatment group and four animals were in the control vehicle only group. Halofuginone injections (5 μg/mouse/day) were initiated immediately after irradiation followed by daily injections. One of the animals in each group was euthanized and the skin was removed at 24, 48, 72, and 96 h post-irradiation. After removal the skin samples were snap-frozen in liquid nitrogen and stored at -70°C for subsequent Western blotting. This experiment was replicated twice.

Western blot analysis. Protein samples of equal amounts were subjected to PAGE on 4-20% Tris-glycine acrylamide gels (Novex-Invitrogen). Following transfer to nitrocellulose by iBlot Gel Transfer Device (Novex-Invitrogen), samples were probed with primary antibodies diluted 1:200-2000, followed by the appropriate secondary antibody diluted to 1:2000 and visualized by chemiluminescence (Perkin-Elmer). To confirm equal protein loading and transfer, membranes were stripped by ReBlot Plus (Chemicon) and reprobed using anti-actin antibody.

Statistical analyses. Mean ± SE was calculated and significance was analyzed using a two-tailed Student’s t-test.

Results

Inhibition of the TGF-β signaling pathway by halofuginone: in vitro studies. To determine the effects of halofuginone on the TGF-β signaling pathway, HaCaT cells were pretreated with or without halofuginone (250 nM) for 24 h. TGF-β was added to the cells for the last 6 h to stimulate the TGF-β pathway. A variety of TGF-β signaling molecules were evaluated by Western blot analysis as shown in Fig. 1. Halofuginone treatment alone resulted in decreases in TGF-βRII, TSP1, pSmad3, and total Smad3 protein levels compared to untreated controls. Smad7 levels increased
marginally following halofuginone treatment. No change in either pSmad2 or total Smad2 levels after halofuginone treatment was observed.

Treatment of cells with TGF-ß alone resulted in increases in both pSmad2 and pSmad3. TSP1 levels were also elevated following TGF-ß treatment; whereas, TGF-ßRII levels were essentially unchanged. Stimulation of TGF-ß signaling molecules was attenuated by combination treatment with halofuginone and TGF-ß, with pSmad3, pSmad2, and TSP1 levels decreased compared to TGF-ß treatment alone. Smad7 and TGF-ßRII levels were unchanged. Collectively, these studies show that halofuginone treatment alone exerts effects on TGF-ß signaling molecules by decreasing activation and/or levels of key proteins in the pathway. When the TGF-ß pathway was stimulated by TGF-ß, halofuginone suppressed the activation/levels of several of the key pathway members.

Halofuginone protects against radiation-induced leg contracture. Our previous studies with halofuginone and radiation-induced leg contracture utilized daily dosing of halofuginone post-radiation treatment (15). In the present study, we sought to determine if less dosing of halofuginone would result in protection. Five daily doses of halofuginone (instead of 7) were given per week for periods extending to 4 months. This protocol more closely resembles how halofuginone might be delivered in a clinical setting. Exposure of control legs to 35 Gy resulted in leg contracture of ~18% and 23% when evaluated at 3 and 4 months post-radiation, respectively as shown in Fig. 2. For this radiation dose, the contraction observed was consistent with our previous studies (15) and other published studies (17). Halofuginone treatment at 1 and 5 μg/mouse resulted in significant protection against radiation-induced leg contraction when evaluated at both 3 and 4 months post-radiation treatment.

Inhibition of the TGF-ß signaling pathway by halofuginone: in vivo. Radiation has been shown to activate the TGF-ß pathway in various normal tissues in vivo (4,5). We next determined if halofuginone treatment could suppress radiation-induced activation of the TGF-ß pathway by collecting skin samples from animals exposed to radiation only and radiation plus daily halofuginone treatment for 4 consecutive days post-radiation. Radiation treatment alone resulted in increases in pSmad3, TSP1, Smad7, and TGFßRII as shown in Fig. 3. pSmad3 levels peaked between 48-72 h post-radiation where they were higher than control levels. pSmad2 levels were unchanged over the time course (data not shown). Radiation treatment induced TSP1 levels with maximum induction at 24 h following radiation where they were higher than control levels. Smad7 levels were also elevated by ~25% over control values over the 24-96 h time course. Daily halofuginone treatment of irradiated animals suppressed radiation-induced activation of TSP1, pSmad3, Smad7, and TGFßRII.

Halofuginone - + - + Halofuginone - + - + TGF-ß - - + + TGF-ßRII Actin TSP1 Actin Smad7 Actin pSmad3 Total Smad3 Actin pSmad2 Total Smad2 Actin

Figure 1. Western blot analysis of proteins extracted from HaCaT cells treated with or without a 24-h pretreatment of 250 nM halofuginone; TGF-ß (2 ng/ml) was added the last 6 h of the halofuginone treatment.

Figure 2. Radiation-induced leg contraction at 3 and 4 months post-radiation treatment without or with halofuginone treatment (hashed column, 1 μg/mouse/day; gray column, 5 μg/mouse/day). Compared to radiation only controls, both doses of halofuginone provided protection at 3 months ( p<0.004; † p<0.00002) and 4 months ( ‡ p<0.002; § p<0.0002) post-radiation treatment.
Discussion

Radiation treatment is known to activate TGF-ß followed by activation of members of the TGF-ß signaling pathway (4,5,9). Exogenously applied TGF-ß will also activate the TGF-ß signaling pathway and was used to evaluate whether halofuginone would be effective in attenuating TGF-ß pathway activation. Treatment of HaCaT cells with exogenous TGF-ß resulted in activation of key members of the TGF-ß signaling pathway, in particular pSmad2 and pSmad3, consistent with our previous studies (15). TGF-ß treatment also induced TSP1 levels in HaCaT cells. Only modest induction was observed for TGF-ßRII. In contrast, treatment of HaCaT cells with halofuginone treatment alone lowered TSP1, pSmad3 and total Smad3 levels. Pretreatment of cells with halofuginone before addition of TGF-ß attenuated activation for pSmad3, total Smad3, and TSP1, suggesting that halofuginone was effective in blunting activation of the TGF-ß pathway. The in vitro studies revealed two characteristics of halofuginone that had not been previously observed. First, halofuginone treatment had been previously shown to enhance production of Smad7 RNA (15); however, protein levels had not been evaluated. The current study demonstrates that halofuginone treatment did not increase Smad7 protein levels in HaCaT cells treated with TGF-ß. Second, halofuginone treatment alone or in combination with TGF-ß activation suppressed levels of TSP1. TSP1 is a homeotrimetric cellular matrix protein and is a co-activator of TGF-ß along with the latency-associated peptide (18). Blocking TGF-ß signaling upstream at the TGF-ß activation step would explain how other downstream members of the TGF-ß pathway would be effected by halofuginone treatment. The mechanism of TSP1 suppression by halofuginone is not known.

In agreement with our previous study, halofuginone treatment post-radiation provided significant protection against radiation-induced leg shortening even though halofuginone was administered daily (Monday through Friday) instead of seven days per week for four months. The extent of protection was slightly less in the present study for both halofuginone doses compared to our previous study. For example, the irradiated leg length (% of control) 4 months after radiation exposure was 85.5 and 88% for 1 and 5 μM halofuginone concentrations, respectively, compared to 97 and 95% for 1 and 5 μM halofuginone concentrations in our previous study. Despite the fact that the same animal strain was used and the radiation/drug conditions were the same, administering halofuginone 7 days per week yielded somewhat better results. The significance of this observation is unclear; however, missing halofuginone doses over the weekends might have allowed for transient recovery of TGF-ß signaling followed partial initiation of pro-fibrotic reactions. Elevated levels of TGF-ß in normal tissues and blood have been observed weeks to months following radiation treatment (19,20), which is consistent with the notion that radiation-induced fibrosis is a chronic ongoing process. Further studies will be required to determine if TGF-ß signaling transiently recovers following 5 daily treatments of halofuginone in irradiated tissues.

Using a halofuginone dosing schedule that provided protection against radiation-induced soft tissue fibrosis, provided the framework to determine if halofuginone given daily after radiation would attenuate the TGF-ß signaling pathway in vivo. Radiation treatment alone to the skin did in fact activate several members of the TGF-ß signaling pathway, including TGF-ßRII, pSmad3, Smad7, and TSP1, persisting in many cases up to 4 days post-radiation (Fig. 3). Daily halofuginone treatment suppressed the induction by radiation of TGF-ßRII, pSmad3, Smad7, and TSP1 suggesting that the protection observed with respect to radiation-induced soft tissue fibrosis was related to attenuation in TGF-ß signaling. The most prominent reduction in induced TGF-ß signaling molecules afforded by halofuginone treatment was with pSmad3, particularly from 48-96 h post-radiation. This
observation is consistent with our earlier observations that Smad3 knock-out mice are resistant to radiation-induced fibrosis (21). Likewise, halofuginone treatment resulted in reduction in both TGF-βRII and TSP1 levels. To a lesser extent, halofuginone treatment lowered Smad7 levels; however, radiation treatment alone only marginally elevated Smad7 levels.

Collectively, the data presented indicate that halofuginone is an effective protector against radiation-induced leg contraction (fibrosis) and the protection is clearly related to halofuginone attenuating the induction of key members of the TGF-β signaling pathway. Of particular interest was the demonstration that radiation induces TSP1 and that halofuginone can inhibit its induction. TSP1 is clearly upstream of the other TGF-β signaling molecules evaluated in this study. It has been shown in certain wild-type p53 cells lines that activated p53 can up-regulate TSP1 expression (22). Given that radiation can activate both p53 and TSP1, we are currently investigating whether halofuginone can modulate the p53 pathway. TSP1 might serve as a biomarker for monitoring the efficacy of halofuginone should it be evaluated in a clinical setting for protection against radiation-induced fibrosis. The protection afforded by halofuginone to normal tissues coupled with its lack of protection against radiation-induced tumor regrowth in preclinical studies (15) makes it a worthy candidate for human clinical trials.

Acknowledgements

This research was supported by the Intramural Research Program, Center for Cancer Research, National Cancer Institute, NIH.

References